RRMMにおける新規薬剤と組み合わせたイサツキシマブ - マスタープロトコル
再発性または難治性の多発性骨髄腫(RRMM)におけるイサツキシマブとポマリドマイドおよびデキサメタゾンを併用したイサツキシマブと新規薬剤との併用でデキサメタゾンを併用または併用しないイサツキシマブを評価する第 1-2 相 UMBRELLA 試験 - マスタープロトコル
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
調査の概要
状態
条件
詳細な説明
Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Trial Transparency email recommended (Toll free number for US & Canada)
- 電話番号:option 6 800-633-1610
- メール:contact-us@sanofi.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- 完了
- University of Alabama at Birmingham- Site Number : 8400001
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Winship Cancer Institute of Emory University- Site Number : 8400010
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- 完了
- University of Illinois-Chicago - College of Medicine- Site Number : 8400007
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Health System - Ann Arbor- Site Number : 8400004
-
-
New York
-
Buffalo、New York、アメリカ、14263
- 募集
- Roswell Park Cancer Institute- Site Number : 8400008
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- The Ohio State University- Site Number : 8400012
-
-
-
-
-
Jerusalem、イスラエル、9112001
- 募集
- Investigational Site Number : 3760002
-
Ramat Gan、イスラエル、5262100
- 募集
- Investigational Site Number : 3760003
-
Tel Aviv、イスラエル、6423906
- 募集
- Investigational Site Number : 3760001
-
-
-
-
Reggio Emilia
-
Meldola、Reggio Emilia、イタリア、47014
- 募集
- Investigational Site Number : 3800001
-
-
-
-
New South Wales
-
Wollongong、New South Wales、オーストラリア、2500
- 募集
- Investigational Site Number : 0360006
-
-
Victoria
-
Heidelberg、Victoria、オーストラリア、3084
- 完了
- Investigational Site Number : 0360003
-
Melbourne、Victoria、オーストラリア、3065
- 募集
- Investigational Site Number : 0360002
-
Richmond、Victoria、オーストラリア、3121
- 募集
- Investigational Site Number : 0360001
-
-
-
-
-
Athens、ギリシャ、115 28
- 募集
- Investigational Site Number : 3000001
-
Athens、ギリシャ、106 76
- 募集
- Investigational Site Number : 3000002
-
-
-
-
-
Frankfurt、ドイツ、60590
- 募集
- Investigational Site Number : 2760006
-
Lübeck、ドイツ、23562
- 募集
- Investigational Site Number : 2760008
-
-
-
-
-
Oslo、ノルウェー、0450
- 募集
- Investigational Site Number : 5780001
-
-
-
-
-
Lille、フランス、59037
- 募集
- Investigational Site Number : 2500002
-
Nantes、フランス、44093
- 募集
- Investigational Site Number : 2500001
-
Paris、フランス、75013
- 募集
- Investigational Site Number : 2500003
-
Paris、フランス、75015
- 募集
- Investigational Site Number : 2500004
-
-
-
-
Puerto Rico
-
Hato Rey、Puerto Rico、プエルトリコ、00917
- 完了
- Puerto Rico Medical Research Center- Site Number : 8400005
-
-
-
-
Seoul-teukbyeolsi
-
Seoul、Seoul-teukbyeolsi、韓国、03722
- 募集
- Investigational Site Number : 4100004
-
Seoul、Seoul-teukbyeolsi、韓国、06351
- 募集
- Investigational Site Number : 4100002
-
Seoul、Seoul-teukbyeolsi、韓国、03080
- 募集
- Investigational Site Number : 4100001
-
Seoul、Seoul-teukbyeolsi、韓国、06591
- 募集
- Investigational Site Number : 4100003
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participant must be 18 years of age inclusive or older.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
-
Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line).
-
RRMM with measurable disease:
- Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
- Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
- Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65).
-
Men or woman or childbearing potential should agree to use contraception.
-
Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.
-
Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.
-
Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.
-
Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.
Exclusion Criteria:
- Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
- Uncontrolled infection within 14 days prior to first study intervention administration.
- Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).
- Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A.
- Uncontrolled or active hepatitis B virus (HBV) infection.
- Active hepatitis C virus (HCV) infection.
- Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
- Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
- Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
- Participants with a contraindication to treatment.
- Vaccination with a live vaccine 4 weeks before the start of the study.
- Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
- Hemoglobin <8 g/dL.
- Platelets <50 × 10^9/L.
- Absolute neutrophil count <1.0 × 10^9/L.
- Creatinine clearance <30 mL/min/1.73m2.
- Total bilirubin >1.5 × ULN, except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
- Aspartate aminotransferase and/or alanine aminotransferase >3 × ULN.
- Patients with grade 3 or 4 hypercalcemia.
Substudy 01:
-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.
Substudy 02:
- History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
- Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
- Prothrombin time or INR >1.5 × upper limit of normal (ULN).
Substudy 03:
- Current corneal epithelial disease except mild punctate keratopathy.
- Patients who have received prior therapy with belantamab mafodotin.
Substudy 04:
- Central nervous system or leptomeningeal disease.
- Medical history of seizure.
- Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
- Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
- Prior allogeneic hematopoietic stem cell transplant (allo-HSCT).
Substudy 05:
- Participant unable to swallow tablets.
Substudy 06:
- History of active autoimmune disorders.
- History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
- Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.
- Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
- Patient with chronic active EBV infection.
- Patients with known history of HLH.
- Hemoglobin < 9 g/dL.
- Prior therapy with any anti-CD47 or anti signal regulatory protein alpha agent.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
他の名前:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Capsule; Route of administration: Oral
他の名前:
|
|
実験的:isatuximab + SAR439459 + dexamethasone (Substudy 02)
SAR439459 in combination with isatuximab and dexamethasone Part 1: 2 dose levels (DLs) of IV SAR439459:
Part 2:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
他の名前:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for injection; Route of administration: Intravenous |
|
実験的:isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)
Belantamab mafodotin in combination with isatuximab and dexamethasone Part 1: 1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:
Part 2:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
他の名前:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
他の名前:
|
|
実験的:Isatuximab + pegenzileukin (Substudy 04)
Pegenzileukin in combination with isatuximab Part 1- dose escalation:
Part 1 - dose optimization:
Part 2 (dose expansion):
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
他の名前:
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
他の名前:
|
|
実験的:Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)
Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.
Part 1- dose optimization:
Part 2- dose expansion:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
他の名前:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: tablet; route of administration: oral
他の名前:
|
|
実験的:Isatuximab + evorpacept + dexamethasone (Substudy 06)
Isatuximab in combination with evorpacept and dexamethasone Part 1- dose escalation:
Part 2- dose expansion:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
他の名前:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
時間枠:Through the end of cycle 1 (approximately 6 weeks)
|
Determination or confirmation of the dose will be based on: safety and tolerability in terms of TEAEs/SAEs, dose-limiting toxicity occurrence, and laboratory parameters available information on PK (if appropriate) and biomarkers. |
Through the end of cycle 1 (approximately 6 weeks)
|
|
Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
新規エージェント(実験腕)とイサトキシマブ(ctrough)の濃度
時間枠:サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
|
|
Belumosudilの最初の注入(CMAX)後に観察される最大濃度-Sududy05
時間枠:サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
|
|
Belumosudil -Sududy 05のcmax(tmax)に到達する時間
時間枠:サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
|
|
Belumosudilの0から8時間(AUC0-8H)の台形法を使用して計算された濃度対時間曲線下面積-Sustudy 05
時間枠:サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
|
|
Evorpacept -Sududy 06の最初の注入(CMAX)後に観察される最大濃度
時間枠:サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
|
|
Evorpacept -sustudy 06のcmax(tmax)に到達する時間
時間枠:サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
|
|
濃度の下での面積と時間曲線は、evorpacept(auc0-t)の投与間隔で台形法を使用して計算された-Sustudy 06
時間枠:サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
サイクル1の間の複数のタイムポイント。サイクルは28日です。
|
|
|
Part 1 (dose finding, experimental substudies): ORR
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, controlled experimental substudies): ORR
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 1 (dose finding, experimental substudies): VGPR or better
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, independent experimental substudies): VGPR or better
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Clinical benefit rate (CBR) in each treatment arm
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
CBR, defined as the proportion of participants with sCR, CR, VGPR, PR, or minimal response, according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Duration of Response (DOR) in each treatment arm
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
DOR, defined as the time from the date of the first response that is subsequently confirmed for patients achieving PR or better to the date of first documented PD or death, whichever happens first. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Time to First Response (TT1R) in each treatment arm
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
TT1R, defined as the time from the date of first treatment to the date of first response (PR or better) that is subsequently confirmed. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Time to Best Response (TTBR) in each treatment arm
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
TTBR, defined as the time from the date of first treatment to the date of first occurrence of best overall response (PR or better) that is subsequently confirmed. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
Safety and tolerability assessed in terms of adverse events/SAEs, including second primary malignancies, laboratory parameters, vital signs, and findings from physical examination. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Progression-free survival (PFS) in each treatment arm
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
PFS is defined as the time from the date of first treatment to disease progression based on the Investigator assessment according to 2016 IMWG criteria or death from any cause, whichever happens first. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Overall Survival (OS) in each treatment arm
時間枠:Up to approximately 28 months after the First patient in or scheduled assessment
|
OS is defined as the time from the date of first treatment to death from any cause. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Immunogenicity of isatuximab and novel agents
時間枠:Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
|
Incidence of anti-drug antibodies (ADAs) for novel agents (experimental arms) and isatuximab. |
Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
|
|
Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)
時間枠:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The EORTC QLQ-C30 will be used to assess cancer-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Disease- and treatment-related quality of life will be assessed using the EORTC multiple myeloma module (QLQ-MY20) questionnaire
時間枠:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The EORTC QLQ-MY20 will be used to measure myeloma-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Global impact of side effects will be assessed using the Functional Assessment of Cancer Therapy (FACT-G) (GP5)
時間枠:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
A single item from the FACT-G GP5 will be used to assess the global impact of side effects. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Estimate/Confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores using the Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales
時間枠:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales will be utilized as anchors to estimate/confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
The intensity of skeletal-related events (SRE)- related bone pain will be assessed using the skeletal-related bone pain numeric rating scale (SRE-BP-NRS) for control and experimental arms -Substudy 02
時間枠:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The SRE-BP-NRS) will be used to assess the intensity of SRE-related bone pain (on average and at its worst) for control arm only |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
SRE Incidence for control and experimental arms- Substudy 02
時間枠:Continuous throughout study assessment (up to approximately 28 months)
|
SRE incidence, defined as the proportion of participants who experienced pathological fracture, radiation to bone, spinal cord compression, or surgery to bone as a first bone event. |
Continuous throughout study assessment (up to approximately 28 months)
|
|
Time to First Occurrence of SRE Assessment for control and experimental arms (Substudy 02)
時間枠:Continuous throughout study assessment (up to approximately 28 months)
|
Time to first occurrence of SRE is defined as time from the date of randomization to the occurrence of first SRE. |
Continuous throughout study assessment (up to approximately 28 months)
|
|
Assessment of Health care resource utilization related with SREs for control and experimental arms -Substudy 02
時間枠:On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
|
The Health Care Resource Use-SREs questionnaire (HCRU-SREs) will be used to assess the use of health care resources associated with these events. |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
|
|
To assess patient-reported visual functioning for experimental arm only -Substudy 03
時間枠:On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.
|
An NEI VFQ-25 will be used to assess patient-reported visual functioning. |
On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Sciences & Operations、Sanofi
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ACT16482
- 2020-003024-16 (EudraCT番号)
- U1111-1244-2598 (レジストリ識別子:ICTRP)
- 2024-514988-25 (レジストリ識別子:CTIS)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。